VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma.

Annemiek BroijlAugustinus C M de JongMark van DuinPieter SonneveldJesper KühnauVincent H J van der Velden

Published in: American journal of clinical pathology (2021)

Both CD38-ME and VS38c allow reliable MRD detection in MM patients, but the high expression of VS38c allows easier identification of MM cells, especially in daratumumab-treated patients.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
peritoneal dialysis
prognostic factors
induced apoptosis
poor prognosis
machine learning
patient reported outcomes
oxidative stress
cell proliferation
quantum dots
sensitive detection
cell cycle arrest
data analysis
artificial intelligence